![]() Overall, the systematic review collected 48 studies from 25 countries and 133,006 participants from the studies were assessed with ISI for insomnia symptoms during the COVID-19 pandemic.Īlrasheed and colleagues wrote that, “a statistically significant difference was observed between countries for all severities of insomnia symptoms. ![]() Included in the analysis were only studies that assessed insomnia using the Insomnia Severity Index (ISI). Seventeen databases and 6 preprint services of relevant studies between November 2019 and August 2021 were explored. 1 Maha Meshal Alrasheed, PhD, MSc associate professor, Clinical Pharmacy Department, College of Pharmacy, King Saud University, and colleagues that their data, “suggests that the COVID-19 pandemic is associated specifically with a marked increase in the rates of subthreshold insomnia symptoms but not moderate or severe insomnia.” There was an estimate of 16.66% that suffered from clinically significant insomnia, where 13.75% of that population suffered from moderate insomnia, and 2.50% suffered from severe insomnia. This review was able to evaluate insomnia symptoms while maintaining data homogeneity by using a single assessment instrument.įrom the pooled analysis, the estimate of insomnia symptoms, both subthreshold and clinically significant, was 52.57%. Previously, there had not been any meta-analytic studies conducted which focused on the prevalence of insomnia symptoms in different COVID-19 patient groups. A recent global systematic review and individual participant data meta-analysis implied in its findings that the COVID-19 pandemic is linked to a significant increase in subthreshold of insomnia symptoms, although not for moderate or severe insomnia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |